<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27207971</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>12</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2047-9980</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>5</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>May</Month>
              <Day>20</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of the American Heart Association</Title>
          <ISOAbbreviation>J Am Heart Assoc</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e003432</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1161/JAHA.116.003432</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Elderly patients with atrial fibrillation are at higher risk of both ischemic and bleeding events compared to younger patients. In a prespecified analysis from the ENGAGE AF-TIMI 48 trial, we evaluate clinical outcomes with edoxaban versus warfarin according to age.</AbstractText>
          <AbstractText Label="METHODS AND RESULTS">Twenty-one thousand one-hundred and five patients enrolled in the ENGAGE AF-TIMI 48 trial were stratified into 3 prespecified age groups: &lt;65 (n=5497), 65 to 74 (n=7134), and ≥75 (n=8474) years. Older patients were more likely to be female, with lower body weight and reduced creatinine clearance, leading to higher rates of edoxaban dose reduction (10%, 18%, and 41% for the 3 age groups, P&lt;0.001). Stroke or systemic embolic event (1.1%, 1.8%, and 2.3%) and major bleeding (1.8%, 3.3%, and 4.8%) rates with warfarin increased across age groups (Ptrend&lt;0.001 for both). There were no interactions between age group and randomized treatment in the primary efficacy and safety outcomes. In the elderly (≥75 years), the rates of stroke/systemic embolic event were similar with edoxaban versus warfarin (hazard ratio 0.83 [0.66-1.04]), while major bleeding was significantly reduced with edoxaban (hazard ratio 0.83 [0.70-0.99]). The absolute risk difference in major bleeding (-82 events/10 000 pt-yrs) and in intracranial hemorrhage (-73 events/10 000 pt-yrs) both favored edoxaban over warfarin in older patients.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Age has a greater influence on major bleeding than thromboembolic risk in patients with atrial fibrillation. Given the higher rates of bleeding and death with increasing age, treatment of elderly patients with edoxaban provides an even greater absolute reduction in safety events over warfarin, compared to treatment with edoxaban versus warfarin in younger patients.</AbstractText>
          <AbstractText Label="CLINICAL TRIAL REGISTRATION">URL: https://www.clinicaltrials.gov/. Unique identifier: NCT00781391.</AbstractText>
          <CopyrightInformation>© 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kato</LastName>
            <ForeName>Eri Toda</ForeName>
            <Initials>ET</Initials>
            <AffiliationInfo>
              <Affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA Tokai University Hospital, Isehara, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giugliano</LastName>
            <ForeName>Robert P</ForeName>
            <Initials>RP</Initials>
            <AffiliationInfo>
              <Affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA rgiugliano@partners.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ruff</LastName>
            <ForeName>Christian T</ForeName>
            <Initials>CT</Initials>
            <AffiliationInfo>
              <Affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Koretsune</LastName>
            <ForeName>Yukihiro</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Osaka National Hospital, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yamashita</LastName>
            <ForeName>Takeshi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>The Cardiovascular Institute, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kiss</LastName>
            <ForeName>Robert Gabor</ForeName>
            <Initials>RG</Initials>
            <AffiliationInfo>
              <Affiliation>Military Hospital, Budapest, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nordio</LastName>
            <ForeName>Francesco</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Murphy</LastName>
            <ForeName>Sabina A</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kimura</LastName>
            <ForeName>Tetsuya</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Daiichi Sankyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jin</LastName>
            <ForeName>James</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Daiichi Sankyo, Parsippany, NJ.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lanz</LastName>
            <ForeName>Hans</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Daiichi Sankyo, Parsippany, NJ.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mercuri</LastName>
            <ForeName>Michele</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Daiichi Sankyo, Parsippany, NJ.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Braunwald</LastName>
            <ForeName>Eugene</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Antman</LastName>
            <ForeName>Elliott M</ForeName>
            <Initials>EM</Initials>
            <AffiliationInfo>
              <Affiliation>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT00781391</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>05</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Am Heart Assoc</MedlineTA>
        <NlmUniqueID>101580524</NlmUniqueID>
        <ISSNLinking>2047-9980</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D065427">Factor Xa Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5Q7ZVV76EI</RegistryNumber>
          <NameOfSubstance UI="D014859">Warfarin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>NDU3J18APO</RegistryNumber>
          <NameOfSubstance UI="C552171">edoxaban</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001281" MajorTopicYN="N">Atrial Fibrillation</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004617" MajorTopicYN="N">Embolism</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065427" MajorTopicYN="N">Factor Xa Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014859" MajorTopicYN="N">Warfarin</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">antithrombotic</Keyword>
        <Keyword MajorTopicYN="Y">bleeding</Keyword>
        <Keyword MajorTopicYN="Y">death</Keyword>
        <Keyword MajorTopicYN="Y">elderly</Keyword>
        <Keyword MajorTopicYN="Y">stroke</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>5</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>5</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27207971</ArticleId>
        <ArticleId IdType="pmc">PMC4889207</ArticleId>
        <ArticleId IdType="doi">10.1161/JAHA.116.003432</ArticleId>
        <ArticleId IdType="pii">JAHA.116.003432</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T, O'Donnell M, Venketasubramanian N, Barker‐Collo S, Lawes CM, Wang W, Shinohara Y, Witt E, Ezzati M, Naghavi M, Murray C; Global Burden of Diseases I, Risk Factors S, the GBDSEG
. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383:245–254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4181600</ArticleId>
            <ArticleId IdType="pubmed">24449944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285:2370–2375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11343485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lin HJ, Wolf PA, Kelly‐Hayes M, Beiser AS, Kase CS, Benjamin EJ, D'Agostino RB. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996;27:1760–1764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8841325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119–125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16818816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I‐III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke. 1999;30:1223–1229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10356104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Perera V, Bajorek BV, Matthews S, Hilmer SN. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing. 2009;38:156–162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19151165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Scowcroft AC, Lee S, Mant J. Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the general practice research database (GPRD) 2000–2009. Heart. 2013;99:127–132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3551210</ArticleId>
            <ArticleId IdType="pubmed">23086966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zimetbaum PJ, Thosani A, Yu HT, Xiong Y, Lin J, Kothawala P, Emons M. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk?
Am J Med. 2010;123:446–453.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20399322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor‐based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263–272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19762550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user‐friendly score (HAS‐BLED) to assess 1‐year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–1100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20299623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hylek EM, D'Antonio J, Evans‐Molina C, Shea C, Henault LE, Regan S. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke. 2006;37:1075–1080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16527999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tulner LR, Van Campen JP, Kuper IM, Gijsen GJ, Koks CH, Mac Gillavry MR, van Tinteren H, Beijnen JH, Brandjes DP. Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study. Drugs Aging. 2010;27:39–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20030431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta‐analysis of randomised trials. Lancet. 2014;383:955–962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24315724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long‐term anticoagulant therapy (RE‐LY) trial. Circulation. 2011;123:2363–2372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21576658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA; Committee RAS Investigators
. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014;130:138–146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24895454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, Deenadayalu N, Jarolim P, Betcher J, Shi M, Brown K, Patel I, Mercuri M, Antman EM. Association between edoxaban dose, concentration, anti‐factor Xa activity, and outcomes: an analysis of data from the randomised, double‐blind ENGAGE AF‐TIMI 48 trial. Lancet. 2015;385:2288–2295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25769361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; Investigators EA‐T
. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24251359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective anticoagulation with factor Xa next generation in atrial fibrillation‐thrombolysis in myocardial infarction study 48 (ENGAGE AF‐TIMI 48). Am Heart J. 2010;160:635–641.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20934556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–2870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11401607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1244564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schulman S, Angeras U, Bergqvist D, Eriksson B, Lassen MR, Fisher W; Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis
. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010;8:202–204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19878532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E; Investigators B, Midland Research Practices N
. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493–503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17693178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, Granger CB, Hanna M, Held C, Husted S, Hylek EM, Jansky P, Lopes RD, Ruzyllo W, Thomas L, Wallentin L. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35:1864–1872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4104493</ArticleId>
            <ArticleId IdType="pubmed">24561548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L; Investigators R‐L
. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE‐LY Trial (randomized evaluation of long‐term anticoagulation therapy). J Am Coll Cardiol. 2014;63:321–328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24076487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. Updated European Heart Rhythm Association Practical Guide on the use of non‐vitamin K antagonist anticoagulants in patients with non‐valvular atrial fibrillation. Europace. 2015;17:1467–1507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26324838</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
